Centrale del Latte d’Italia — Sales improvement

Centrale del Latte d'Italia

Sales improvement

FY17 results

Food & beverages

19 March 2018

Price	€3.29
Market cap	€46m

Net debt (€m) at 31 December 2017		62.4

Shares in issue		14.0m
Free float		37%
Code		CLI

Primary exchange	STAR (Borsa Italiana)
Secondary exchange		N/A

Share price performance

%	1m	3m	12m
Abs	(2.4)	(3.1)	13.4
Rel (local)	(2.6)	(5.8)	(0.4)

52-week high/low

€4.34

€2.78

Business description

Centrale del Latte d'Italia produces and distributes fresh and long-life milk (UHT and ESL) and dairy products such as cream, yoghurt and cheese. It has a leading position in milk in the Piedmont region of northern Italy and it has expanded to the Veneto, Liguria and Tuscany regions.

Next events

AGM	26 April 2018
Q118 results	10 May 2018
H118 results	02 August 2018
9M18 results	30 October 2018

Analysts

Sara Welford	+44 (0)20 3077 5700
Paul Hickman	+44 (0)20 3681 2501

consumer@edisongroup.com

Edison profile page

Centrale del Latte d'Italia is a research client of Edison Investment Research Limited

Centrale del Latte d’Italia’s (CLI) price increases, implemented during H1, continue to drive revenue growth, with total revenue of €187m in FY17 above our forecast of €181m. Newer initiatives, such as vegetable-based drinks and the export business continue to generate good growth. We have raised our revenue forecasts to reflect the higher FY17 base, but trim our EBITDA forecast as the FY17 figure was below our forecast. Now that the CLF business has been owned for a full year, revenue synergies are coming through and there has been scope for some cost efficiencies. We therefore raise our medium-term EBIT margin growth by 10bp per annum to capture the potential for further cost containment. Our fair value rises to €3.30/share (from €3.25 previously).

Year end	Total revenue (€m)	PBT* (€m)	EPS* (c)	DPS (c)	P/E (x)	Yield (%)
12/16	119.8	(2.09)	(19.57)	6.00	N/A	1.8
12/17	187.5	(0.03)	(1.63)	6.00	N/A	1.8
12/18e	184.4	0.33	1.54	6.00	215.2	1.8
12/19e	186.2	1.36	6.30	6.00	52.6	1.8

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Price increases still driving revenue growth

Price increases were implemented on 1 April 2017 to offset some cost inflation and were fully rolled out on 1 June. We believe organic growth was c 6% for FY17, which is impressive. 2017 represents the first full year of ownership of the CLF business and indeed, FY17 EBITDA was affected by one-off costs of €220,000.

Raw material costs rising again

We note raw material costs started to increase again towards the end of FY17. We therefore trim our EBITDA forecast for FY18, which has a sequential effect on subsequent years. Given the level of gearing, the cut is more significant at the EPS level. We believe there is some scope for ongoing cost containment as a result of the merger with CLF: we note that labour costs were down 120bp as a percentage of revenues in FY17, as any retiring personnel are not being replaced. As a result of this, we also raise our medium-term EBIT margin growth to 10bp per annum (from 0bp). We leave our terminal EBIT margin assumption unchanged at 3%.

Valuation: Fair value of €3.30 per share

Our DCF model points to a fair value of €3.30 per share (from €3.25), implying that the stock is fairly valued. We calculate that for FY19e CLI now trades on a P/E of 52.6x and EV/EBITDA of 12.5x, with a dividend yield of 1.8%. The P/E is inflated in part due to the high interest costs as a result of the elevated level of debt in the short term associated with the merger by incorporation with CLF in September 2016. On EV/EBITDA, CLI trades at a premium of c 45% to our peer group of dairy processors.

FY17 results review

CLI’s total FY17 value of production (total revenue) of €187.5m compares to €119.8m in FY16. Net revenue/sales came in at €183.4m vs €117.8m in FY16. The majority of the growth was of course due to the merger with CLF. FY17 EBITDA of €7.2m (or €7.5m in underlying terms, as discussed above) compares with €2.9m in FY16, with margins up 150bp to 3.9%. Margin recovery was a feature in FY17 following the implementation of the price increases and also better cost control.

We note that vegetable drinks had a strong performance in FY17 as consumers continue to embrace vegetarian, vegan and generally low-fat diets, while consumers with lactose allergies or intolerances seek alternative products. Export sales also more than doubled, as CLI expanded the number of markets into which it exports and also introduced innovative sales channels.

The group successfully completed a €15m bond issue during the latter part of FY17, which allows it to diversify its sources of debt. We note the terms were attractive, with a 3.25% coupon.

Near-term estimates revisions

We raise our revenue forecasts to reflect the FY17 revenues coming in above our forecast. We trim our margin forecasts in light of milk farmgate prices continuing to increase. Our FY18 EBITDA forecast decreases to €7.8m (from €8.9m) and net income reduces to €0.22m from €0.52m. We illustrate the changes to our key forecasts in Exhibit 1.

Exhibit 1: Old vs new near-term forecasts

€000s	FY18e			FY19e			FY20e
€000s	Old	New	% change	Old	New	% change	Old	New	% change
Total revenue	181,903	184,364	1.4	182,812	186,208	1.9	183,726	188,070	2.4
EBITDA	8,852	7,834	(11.5)	9,261	8,285	(10.5)	9,675	8,744	(9.6)
PBT	804	331	(58.8)	1,815	1,356	(25.3)	2,215	1,763	(20.4)
Net income (reported)	523	215	(58.8)	1,180	882	(25.3)	1,439	1,146	(20.4)
EPS (reported), €	0.04	0.02	(58.8)	0.08	0.06	(25.3)	0.10	0.08	(20.4)
Source: Edison Investment Research

Valuation

CLI’s share price performance has been broadly in line with the FTSE MIB on a three-month and 12-month basis, although the share price has outperformed on a six-month basis following the announcement of the agreement with Alibaba. On 2019 estimates, CLI trades on a P/E of 52.6x and EV/EBITDA of 12.5x, with a dividend yield of 1.8%. The P/E is inflated due to the high level of debt following the merger, and hence the high interest costs.

On EV/EBITDA, CLI trades at a premium of c 45% to the average of our peer group of dairy processors, although we note that the companies in our peer group are much larger than CLI.

Exhibit 2: Benchmark valuation of CLI relative to peers

	Market cap (m)	P/E (x)		EV/EBITDA (x)		Dividend yield (%)
	Market cap (m)	2018e	2019e	2018e	2019e	2018e	2019e
Parmalat	€156.6	17.8	N/A	9.6	N/A	1.7	N/A
Dairy Crest	€5,556.2	25.0	21.4	9.3	8.2	0.6	0.6
Dean Foods	£773.5	14.1	13.5	10.4	10.2	4.3	4.5
Saputo	$839.6	11.5	10.4	4.9	4.1	4.3	5.3
Peer group average		17.3	15.5	9.1	8.3	2.7	3.1
CLI	€46.3	215.2	52.6	13.2	12.5	1.8	1.8
Premium/(discount) to peer group (%)		1,146.7%	238.2%	45.2%	50.8%	(33.7%)	(40.6%)

Source: Edison Investment Research estimates and Bloomberg consensus. Note: Prices at 8 March 2018.

Our DCF is based on our (unchanged) assumptions of a 1.5% terminal growth rate and 3% terminal EBIT margin. Our WACC of 5.8% is based on an equity risk premium of 4.5%, a borrowing spread of 5% and beta of 0.9. Below, we show a sensitivity analysis to these assumptions and note that the current share price is discounting a terminal growth rate of 1.5% with a terminal EBIT margin of 3% (which compares to CLT’s pre-merger reported EBIT margin of 2.7% in 2014 and 1.6% in 2015).

Exhibit 3: DCF sensitivity (€/share) to terminal growth rate and EBIT margin

		Terminal EBIT margin
		2.0%	2.5%	3.0%	3.5%	4.0%	4.5%
Terminal growth	0.0%	1.00	1.55	2.10	2.65	3.19	3.74
	0.5%	1.21	1.82	2.42	3.02	3.63	4.23
	1.0%	1.47	2.14	2.81	3.48	4.15	4.82
	1.5%	1.79	2.54	3.30	4.04	4.79	5.54
	2.0%	2.19	3.05	3.90	4.75	5.60	6.46
	2.5%	2.72	3.70	4.69	5.67	6.66	7.65
	3.0%	3.43	4.59	5.76	6.92	8.09	9.26
	3.5%	4.44	5.86	7.29	8.71	10.13	11.56
	4.0%	6.01	7.83	9.65	11.48	13.30	15.12

Source: Edison Investment Research

Exhibit 4: Financial summary

31-December	€'000s	2014	2015	2016	2017e	2018e	2019e	2020e
INCOME STATEMENT		IFRS	IFRS	IFRS	IFRS	IFRS	IFRS	IFRS
Total revenue (value of production)*		102,558	98,319	119,762	187,478	184,364	186,208	188,070
Cost of Sales		(82,415)	(78,796)	(98,652)	(153,937)	(150,287)	(151,604)	(152,932)
Gross Profit		20,143	19,523	21,110	33,541	34,077	34,604	35,138
EBITDA		5,845	4,851	2,905	7,245	7,834	8,285	8,744
Normalised operating profit		2,752	1,554	(1,254)	864	1,920	2,951	3,356
Amortisation of acquired intangibles		0	0	0	0	0	0	0
Exceptionals		(134)	145	(355)	(202)	0	0	0
Share-based payments		0	0	0	0	0	0	0
Reported operating profit		2,618	1,699	(1,609)	661	1,920	2,951	3,356
Net Interest		(811)	(678)	(692)	(996)	(1,696)	(1,701)	(1,700)
Joint ventures & associates (post tax)		(4)	(418)	(143)	107	107	107	107
Exceptionals		0	0	13,903	(81)	0	0	0
Profit Before Tax (norm)		1,937	458	(2,089)	(106)	331	1,356	1,763
Profit Before Tax (reported)		1,803	603	11,459	(309)	331	1,356	1,763
Reported tax		(1,012)	(87)	556	47	(116)	(475)	(617)
Profit After Tax (norm)		809	30	(2,153)	(310)	215	882	1,146
Profit After Tax (reported)		791	517	12,015	(261)	215	882	1,146
Minority interests		0	0	0	0	0	0	0
Discontinued operations		0	0	0	0	0	0	0
Net income (normalised)		809	30	(2,153)	(310)	215	882	1,146
Net income (reported)		791	517	12,015	(261)	215	882	1,146

Basic average number of shares outstanding (m)		10	10	11	14	14	14	14
EPS - basic normalised (€)		0.08	0.00	(0.20)	(0.02)	0.02	0.06	0.08
EPS - diluted normalised (€)		0.08	0.00	(0.20)	(0.02)	0.02	0.06	0.08
EPS - basic reported (€)		0.08	0.05	1.09	(0.02)	0.02	0.06	0.08
Dividend (€)		0.06	0.06	0.06	0.06	0.06	0.06	0.06

Revenue growth (%)		2.6	(4.1)	21.8	56.5	(1.7)	1.0	1.0
Gross Margin (%)		19.6	19.9	17.6	17.9	18.5	18.6	18.7
EBITDA Margin (%)		5.7	4.9	2.4	3.9	4.2	4.4	4.6
Normalised Operating Margin		2.7	1.6	-1.0	0.5	1.0	1.6	1.8

BALANCE SHEET
Fixed Assets		64,185	64,540	129,773	132,731	132,717	132,969	133,224
Intangible Assets		11,706	11,539	19,484	19,521	19,507	19,493	19,479
Tangible Assets		51,671	52,010	107,335	110,817	110,817	111,083	111,352
Investments & other		808	992	2,954	2,393	2,393	2,393	2,393
Current Assets		36,689	41,122	60,457	78,611	73,102	73,297	73,758
Stocks		3,438	3,541	7,698	9,114	8,898	8,976	9,055
Debtors		15,720	14,370	28,209	31,449	31,606	31,922	32,241
Cash & cash equivalents		10,051	12,192	9,521	25,475	20,024	19,825	19,888
Other		7,481	11,019	15,030	12,573	12,573	12,573	12,573
Current Liabilities		(33,232)	(35,004)	(68,199)	(77,372)	(77,437)	(77,842)	(78,251)
Creditors		(23,744)	(24,247)	(42,910)	(46,223)	(46,288)	(46,694)	(47,103)
Tax and social security		(468)	(357)	(697)	(914)	(914)	(914)	(914)
Short term borrowings		(9,021)	(10,401)	(24,592)	(30,234)	(30,234)	(30,234)	(30,234)
Other		0	0	0	0	0	0	0
Long-term Liabilities		(27,178)	(29,847)	(58,489)	(70,874)	(65,910)	(65,910)	(65,910)
Long-term borrowings		(18,219)	(22,446)	(45,159)	(57,624)	(57,624)	(57,624)	(57,624)
Other long term liabilities		(8,960)	(7,402)	(13,330)	(13,250)	(8,286)	(8,286)	(8,286)
Net Assets		40,464	40,810	63,542	63,097	62,472	62,514	62,820
Minority interests		0	0	0	0	0	0	0
Shareholders' equity		40,464	40,810	63,542	63,097	62,472	62,514	62,820

CASH FLOW
Op Cash Flow before WC and tax		5,845	4,851	2,905	7,245	7,834	8,285	8,744
Working capital		1,811	(1,942)	(30)	1,547	124	12	11
Exceptional & other		(129)	(1,262)	(15,092)	(359)	107	107	107
Tax		(1,012)	(87)	556	47	(116)	(475)	(617)
Net operating cash flow		6,515	1,560	(11,661)	8,480	7,949	7,928	8,245
Capex		(2,107)	(3,914)	(4,095)	(9,849)	(5,900)	(5,586)	(5,642)
Acquisitions/disposals		0	0	0	0	0	0	0
Net interest		(811)	(678)	(692)	(996)	(1,696)	(1,701)	(1,700)
Equity financing		0	0	0	0	0	0	0
Dividends		(600)	(600)	(600)	0	(840)	(840)	(840)
Other		2,293	5,031	(1,131)	21,436	0	0	0
Net Cash Flow		5,291	1,399	(18,178)	19,071	(487)	(199)	63
Opening net debt/(cash)		19,950	17,189	20,654	60,230	62,383	67,833	68,032
FX		0	0	0	0	0	0	0
Other non-cash movements		(2,529)	(4,865)	(21,397)	(21,224)	(4,964)	0	0
Closing net debt/(cash)		17,189	20,654	60,230	62,383	67,833	68,032	67,969

Source: Edison Investment Research, company accounts. *Note: Total revenue as defined by the company: revenue from sales and services plus changes in inventories and other revenue and income.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Centrale del Latte d'Italia and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2018. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

Sydney +61 (0)2 8249 8342

Level 12, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity strategy and market outlook – March 2024

Equity strategy and market outlook – February 2024

Equity strategy and market outlook – January 2024

Thematics

Latest

Listed private equity – Performing a balancing act

ConsumerWatch – At least someone loves me

MediaWatch – Rinse and repeat

Audiovisual

Latest

IP Group – executive interview

Take on Trusts – March 2024

Oakley Capital Investments – executive interview

About Edison

About Edison

Careers

Centrale del Latte d’Italia — Sales improvement

Latest

IP Group — Several potential portfolio catalysts on the horizon

Actinogen Medical — First patient dosed in Phase IIb XanaMIA study

Cereno Scientific — CS014 (thrombosis) progresses towards the clinic

Tetragon Financial Group — FY23 growth driven by idiosyncratic factors

Cloudberry Clean Energy — Transformative FY23 with revenue rocketing

Rockhopper Exploration — Operator confident in 2018 Sea Lion Phase 1 FID

Subscribe to Edison